Leadership & Pay ·
Alterity Therapeutics approves CEO Dr David Stamler's revised remuneration package effective 15 October
PRNAFAlterity Therapeutics Ltd
The Board of Directors has approved changes to the total remuneration package for Chief Executive Officer and Managing Director Dr David Stamler, effective from 15 October 2026. The revision reflects market comparables and the company's increasing activities. Key terms include a base salary of US$525,000 per annum and a short-term incentive of up to 100% of that amount. The package includes significant severance provisions for termination without cause and change-of-control protections, such as immediate vesting of unvested equity awards. Alterity intends to seek shareholder approval at its upcoming annual general meeting specifically for the termination benefits included in the revised agreement. Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating disease modifying therapies for neurodegenerative diseases like Parkinson’s and Multiple System Atrophy.